A detailed history of Tower Research Capital LLC (Trc) transactions in Vor Biopharma Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 4,298 shares of VOR stock, worth $3,739. This represents 0.0% of its overall portfolio holdings.

Number of Shares
4,298
Previous 15,610 72.47%
Holding current value
$3,739
Previous $15,000 80.0%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$0.7 - $1.1 $7,918 - $12,443
-11,312 Reduced 72.47%
4,298 $3,000
Q2 2024

Aug 13, 2024

BUY
$1.0 - $2.2 $13,999 - $30,797
13,999 Added 868.96%
15,610 $15,000
Q1 2024

May 15, 2024

SELL
$1.8 - $2.85 $6,667 - $10,556
-3,704 Reduced 69.69%
1,611 $3,000
Q4 2023

Feb 13, 2024

SELL
$1.66 - $2.63 $17,207 - $27,262
-10,366 Reduced 66.11%
5,315 $11,000
Q3 2023

Nov 14, 2023

BUY
$2.1 - $3.35 $28,520 - $45,496
13,581 Added 646.71%
15,681 $33,000
Q2 2023

Aug 14, 2023

BUY
$3.09 - $5.33 $6,489 - $11,193
2,100 New
2,100 $6,000
Q4 2022

Feb 10, 2023

SELL
$3.77 - $7.43 $78,336 - $154,387
-20,779 Reduced 44.53%
25,881 $172,000
Q3 2022

Nov 10, 2022

BUY
$3.9 - $5.52 $98,077 - $138,816
25,148 Added 116.9%
46,660 $186,000
Q2 2022

Aug 15, 2022

SELL
$3.89 - $6.44 $37,974 - $62,867
-9,762 Reduced 31.21%
21,512 $107,000
Q1 2022

May 12, 2022

BUY
$6.04 - $12.23 $77,456 - $156,837
12,824 Added 69.51%
31,274 $189,000
Q4 2021

Feb 14, 2022

BUY
$11.32 - $18.02 $200,590 - $319,314
17,720 Added 2427.4%
18,450 $215,000
Q3 2021

Nov 15, 2021

SELL
$12.24 - $20.38 $2,472 - $4,116
-202 Reduced 21.67%
730 $11,000
Q2 2021

Aug 16, 2021

BUY
$18.65 - $38.78 $9,380 - $19,506
503 Added 117.25%
932 $17,000
Q1 2021

May 17, 2021

BUY
$30.96 - $54.08 $13,281 - $23,200
429 New
429 $18,000

Others Institutions Holding VOR

About Vor Biopharma Inc.


  • Ticker VOR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,056,300
  • Market Cap $33.1M
  • Description
  • Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AM...
More about VOR
Track This Portfolio

Track Tower Research Capital LLC (Trc) Portfolio

Follow Tower Research Capital LLC (Trc) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

News

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.